

Fact Sheet



Company overview

GlobeImmune® is a private biopharmaceutical company developing therapeutic vaccines called Tarmogens® for the treatment of cancer and infectious diseases. The company's lead infectious disease product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). The company's lead oncology programs, GI-4000 and GI-6207, target cancers caused by mutated versions of the Ras oncoprotein and CEA expressing tumors, respectively. GI-4000 is being investigated in clinical trials for the treatment of cancers expressing mutated Ras, including non-small cell lung cancer, pancreatic cancer and colorectal cancer. GI-6207 is being evaluated in clinical trials in patients with CEA expressing tumors. In clinical trials, Tarmogens have been well-tolerated, generated antigen-specific T cell immune responses and improved clinical outcomes in patients.

GI-5005 for chronic hepatitis C infection (HCV)

The GI-5005 Tarmogen elicits an HCV-specific T cell response designed to clear infected liver cells. In a randomized phase 2b study of 140 patients chronically infected with genotype 1 HCV, GI-5005 was administered in combination with standard of care (SOC), compared with administration of SOC alone and demonstrated:

- ◆ Improved viral clearance, biochemical markers and biopsies
- ◆ Excellent safety and tolerability
- ◆ Pharmacogenomic targeting with a 60% viral clearance advantage over SOC alone in IL28B T/T patients
- ◆ The potential as a future backbone for interferon-free treatment of HCV
- ◆ First successful therapeutic vaccine treating chronic infection

The phase 2b study is being expanded, treating a total of 27 *IL28B* T/T patients to better quantify the treatment effect in this high-need population.

GI-4000 for mutated-Ras cancers

The GI-4000 Tarmogen is designed to treat cancers caused by mutations in a cellular protein called Ras. Mutations in Ras lead to uncontrolled cell division and are an underlying cause of approximately 170,000 cases of cancer in the US annually including pancreas, NSCLC, colorectal and ovarian cancers.

- ◆ Only advanced clinical product for Ras mutated cancers
- ◆ Excellent safety and tolerability
- ◆ Highly immunologically active in oncology patients

GI-6207 for CEA-expressing cancers

The GI-6207 Tarmogen targets cancers expressing carcinoembryonic antigen (CEA). A phase 1 dose escalation trial was conducted at the NCI demonstrating excellent safety/tolerability, robust immune and correlated clinical and biomarker responses in late-stage oncology patients.


- ◆ A phase 2 trial in medullary thyroid cancer is being initiated at the NCI

Corporate Highlights

- ◆ Proprietary platform technology
- ◆ Three Tarmogens in phase 2 trials
- ◆ Platform validating results from a phase 2b trial chronic HCV
- ◆ Global alliance with the Celgene Corporation in oncology that includes \$40 million upfront, >\$500 million in milestone payments, plus royalties
- ◆ Global alliance with Gilead Sciences to develop Tarmogens to treat chronic hepatitis B infection.
- ◆ Over \$160 million raised to date in support of the clinical programs

Tarmogen Technology

Tarmogen® products are whole, heat killed recombinant *S. cerevisiae* yeast that express one or more disease-associated proteins. Tarmogens are avidly taken up by antigen presenting cells, such as dendritic cells and macrophages, generating activated T cells capable of locating and eliminating any cell expressing the same disease-related protein. The unique composition of the Tarmogen vector also suppresses the regulatory T cell response, further amplifying immune activity.



Leadership

Executive Management

Timothy C. Rodell, M.D.

President & Chief Executive Officer

David Apelian, M.D., Ph.D., MBA

Chief Medical Officer

C. Jeffrey Dekker

VP Finance

John Frenz, Ph.D.

VP Operations & Manufacturing

Donald Bellgrau, Ph.D.

Founding Scientist

Richard Duke, Ph.D.

Founding Scientist

Alex Franzusoff, Ph.D.

Founding Scientist

Board of Directors

Ralph E. Christoffersen, Ph.D.

Morgenthaler Ventures

J. William Freytag, Ph.D.

Augustine J. Lawlor

HealthCare Ventures

Paul A. Mieyal Ph.D., CFA

Wexford Capital LLC

Dan Mitchell

Sequel Venture Partners

Timothy C. Rodell, M.D.

President & Chief Executive Officer

Pennina Safer, Ph.D.

Medica Venture Partners

Ed Torres

Lilly Ventures

Investors

Adams Street Partners

Biogen-Idec, Inc.

Boston Life Science Venture

BSI SA & Generali

Celgene, Inc.

China Investment & Development

Eminent Venture Capital

GC&H

Genentech, Inc.

HealthCare Ventures

Lilly Ventures

Medica Venture Partners

Mellon Family Investment Co.

Morgenthaler Ventures

PAC-LINK Bio-Venture Capital

Partners Healthcare

Sequel Venture Partners

WRF Capital

Wexford Capital

Yasuda Enterprise Development

Pipeline

INFECTIOUS DISEASES		ONCOLOGY					
PRODUCT	ANTIGEN	INDICATION	RESEARCH	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
GI-5005	NS3/Core	Hepatitis C	[Progress bar spanning Research, Preclinical, Phase 1, and Phase 2]				
GI-2010	Gag	HIV	[Progress bar spanning Research and Preclinical]				
GI-13000	SPEX/SCORE	Hepatitis B	[Progress bar in Research]				
GI-9000	Various	Fungal	[Progress bar in Research]				
GI-4000	Mutated Ras	Pancreas, NSCLC, CRC	[Progress bar spanning Research, Preclinical, Phase 1, and Phase 2]				
GI-6207	CEA	Medullary thyroid cancer	[Progress bar spanning Research, Preclinical, and Phase 1]				
GI-6301	Brachyury	Triple negative breast cancer	[Progress bar spanning Research and Preclinical]				

Financing History

Series A: \$8 million

Led by Sequel Venture Partners
June 2003

Series B: \$38.3 million

Led by Lilly Ventures
September 2005

Series C: \$41.2 million

Led by Wexford Capital
July 2007

Series D: \$10 million

Equity component of \$40 million
upfront payment by Celgene
May 2009

Series E: \$18 million

Led by BSI Healthcapital SA / Generali
January 2010

Total Venture Financing: \$115.5 million

Non-dilutive Financing: \$45.2 million

GlobeImmune, Inc.

1450 Infinite Dr.
Louisville, CO 80027 USA

Phone: 1-303-625-2700

Fax: 1-303-625-2710

E-mail: info@globeimmune.com

TARGETED MOLECULAR IMMUNOTHERAPY

